Broncus Holding Corp. (HK:2216)
:2216
Top Page
Broncus Holding Corp.
(2216)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$2.00
▼(-15.25% Downside)
Action:ReiteratedDate:02/03/26
The score is held down primarily by weak financial performance (persistent losses, declining revenue, and poor cash generation). Technical indicators also point to a continuing downtrend despite oversold readings. Valuation provides limited support because a negative P/E reflects ongoing losses and no dividend data is available.
Positive Factors
High Gross Margin
A ~75.5% gross margin indicates strong unit economics and pricing power for its bronchoscopic devices. Durable product-level margins can sustain R&D and regulatory costs, buffer operating losses, and improve the company's ability to scale profitably if revenue stabilizes over months.
Negative Factors
Sustained Revenue Declines
A ~30.6% revenue decline over the recent period signals persistent loss of sales momentum. Continued top-line contraction undermines scale, weakens fixed-cost absorption, reduces pricing leverage, and limits resources available for product development and commercial expansion over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A ~75.5% gross margin indicates strong unit economics and pricing power for its bronchoscopic devices. Durable product-level margins can sustain R&D and regulatory costs, buffer operating losses, and improve the company's ability to scale profitably if revenue stabilizes over months.
Read all positive factors
Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$724.37M
Dividend YieldN/A
Average Volume (3M)2.03M
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-30.60%
EPS Growth28.61%
CountryHK
Employees200
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.22
Price to Sales (P/S)4.56
P/FCF Ratio-3.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Broncus Holding Corp. Business Overview & Revenue Model
Company Description
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such ...
How the Company Makes Money
Broncus Holding Corp. generates revenue primarily through the sale of its medical devices and related products to hospitals, clinics, and healthcare providers. Key revenue streams include direct sales of its bronchoscopic devices and consumables, ...
Broncus Holding Corp. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.08M | 8.13M | 10.26M | 9.41M | 10.89M | 3.26M |
| Gross Profit | 4.40M | 6.14M | 7.23M | 7.32M | 8.74M | 2.51M |
| EBITDA | -20.69M | -18.96M | -25.06M | -30.58M | -233.31M | -45.95M |
| Net Income | -15.15M | -15.30M | -28.09M | -28.04M | -236.18M | -48.24M |
Balance Sheet | ||||||
| Total Assets | 165.67M | 175.90M | 195.81M | 221.94M | 252.81M | 39.88M |
| Cash, Cash Equivalents and Short-Term Investments | 130.52M | 139.11M | 156.88M | 187.91M | 227.21M | 18.79M |
| Total Debt | 47.00K | 318.00K | 2.35M | 1.47M | 1.95M | 6.12M |
| Total Liabilities | 5.29M | 6.42M | 10.44M | 8.48M | 10.39M | 162.32M |
| Stockholders Equity | 160.38M | 169.48M | 185.37M | 213.46M | 242.42M | -120.51M |
Cash Flow | ||||||
| Free Cash Flow | -5.99M | -10.32M | -26.84M | -31.81M | -33.38M | -16.76M |
| Operating Cash Flow | -5.91M | -10.00M | -26.13M | -30.95M | -31.49M | -15.59M |
| Investing Cash Flow | -21.16M | -25.91M | 5.49M | -87.57M | -1.75M | -1.09M |
| Financing Cash Flow | -3.21M | -1.02M | -1.46M | -572.00K | 241.82M | 32.23M |
Broncus Holding Corp. Technical Analysis
Neutral
2.36
Price Trends
1.60
Negative
2.03
Negative
2.41
Negative
Market Momentum
-0.10
Negative
50.36
Neutral
78.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Neutral. The current price of 2.36 is above the 20-day moving average (MA) of 1.26, above the 50-day MA of 1.60, and below the 200-day MA of 2.41, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 50.36 is Neutral, neither overbought nor oversold. The STOCH value of 78.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2216.
Broncus Holding Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.87B | 22.44 | 3.90% | ― | 32.93% | ― | |
53 Neutral | HK$965.82M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$547.05M | -2.91 | -21.93% | ― | 11.43% | 4.88% | |
44 Neutral | HK$3.12B | -495.98 | -1.35% | ― | 49.86% | 80.35% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$724.37M | -4.03 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2216
Broncus Holding Corp.
1.37
0.54
65.06%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.00
-0.85
-29.82%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.40
1.48
25.00%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.38
20.99%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
48.16
21.46
80.37%
Broncus Holding Corp. Corporate Events
Broncus’ COPD Device Accepted for China’s Innovative Medical Device Fast-Track Review
Jan 12, 2026
Broncus Holding Corporation announced that its BroncTarget® Targeted Lung Denervation Radiofrequency Ablation System has been accepted into China’s National Medical Products Administration Innovative Medical Device Special Review Proced...
Broncus Holding to Buy US$15 Million Stake in Structural Heart Intervention Player
Dec 29, 2025
Broncus Holding Corporation has agreed, through a wholly owned subsidiary, to acquire 157,800 Series B preferred shares in an unnamed target company for US$15 million, representing 1.05% of the target’s fully diluted share capital. The cash ...
Broncus Holding Corp. Updates on Share Issue and Strategic Fund Allocation
Nov 21, 2025
Broncus Holding Corp. has announced an update on its proposed issue of shares under a general mandate, with the completion of necessary regulatory approvals in progress. The company plans to utilize the net proceeds of approximately HK$326.5 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.